Immunocore

Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.
Company Growth (employees)
Type
Private
HQ
Milton, GB
Size (employees)
308 (est)+6%
Immunocore is headquartered in Milton, GB

Key People/Management at Immunocore

Eliot Forster

Eliot Forster

CEO
Christina Coughlin

Christina Coughlin

Chief Medical Officer
Bent Jakobsen

Bent Jakobsen

Chief Scientific Officer
Eva-Lotta Allan

Eva-Lotta Allan

Chief Business Officer
Namir Hassan

Namir Hassan

Director of Translational Research & Development
Henrik Sorensen

Henrik Sorensen

Head of Alliance Management

Immunocore Office Locations

Immunocore has an office in Milton
Milton, GB (HQ)
101 Park Dr
Milton, GB (HQ)
101 Park Drive, Milton Park, Abingdon, Oxon

Immunocore Financials and Metrics

Summary Metrics

Total Funding

$320 m

Latest funding size

$320 m

Time since last funding

over 2 years

Investors

Immunocore's latest funding round in July 2015 was reported to be $320 m. In total, Immunocore has raised $320 m

Immunocore Financials

Immunocore's revenue was reported to be £16.5 m in FY, 2016 which is a 15% increase from the previous period.
GBP

Revenue (FY, 2016)

16.5 m

Net income (FY, 2016)

(40.8 m)

EBITDA (FY, 2016)

(51.7 m)

EBIT (FY, 2016)

(54.4 m)

Cash (31-Dec-2016)

176.6 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2 m6.4 m14.3 m16.5 m

Revenue growth, %

212%

Operating expense total

6.8 m13.7 m(2.9 m)70.9 m

EBITDA

(4.4 m)(7.3 m)18.9 m(51.7 m)
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.7 m)(5.6 m)16.8 m(40.8 m)

Cash From Operating Activities

11.3 m40.3 m(22.4 m)(38 m)

Cash From Financing Activities

3 m404 k197.7 m96 k

Net Change in Cash

13.8 m34.5 m168.9 m(43.1 m)
    GBPY, 2016

    Revenue/Employee

    102 k

    Financial Leverage

    1.3 x
    Show all financial metrics

    Immunocore's Web-traffic and Trends

    Immunocore Online and Social Media Presence

    Immunocore Company Life and Culture

    You may also be interested in